MSCs inhibited naive CD4+ T cells of SS patients to differentiate into cTfh cells via secreting indoleamine 2,3-dioxygenase (IDO) with high enzymic activity, which could be partly reversed by the IDO inhibitor 1-MT (128). Here, IDO1 is linked to synovial sarcoma.